225 related articles for article (PubMed ID: 10930538)
1. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
Yang CH; Schneider E; Kuo ML; Volk EL; Rocchi E; Chen YC
Biochem Pharmacol; 2000 Sep; 60(6):831-7. PubMed ID: 10930538
[TBL] [Abstract][Full Text] [Related]
2. Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.
Yang CH; Chen YC; Kuo ML
Anticancer Res; 2003; 23(3B):2519-23. PubMed ID: 12894535
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard M; van Gastelen MA; de Jong LA; Pluim D; van Waardenburg RC; Ruevekamp-Helmers MC; Floot BG; Schellens JH
Cancer Res; 1999 Sep; 59(18):4559-63. PubMed ID: 10493507
[TBL] [Abstract][Full Text] [Related]
4. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Yang CJ; Horton JK; Cowan KH; Schneider E
Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272
[TBL] [Abstract][Full Text] [Related]
6. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Honjo Y; Hrycyna CA; Yan QW; Medina-Pérez WY; Robey RW; van de Laar A; Litman T; Dean M; Bates SE
Cancer Res; 2001 Sep; 61(18):6635-9. PubMed ID: 11559526
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
8. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
9. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
[TBL] [Abstract][Full Text] [Related]
10. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).
Litman T; Brangi M; Hudson E; Fetsch P; Abati A; Ross DD; Miyake K; Resau JH; Bates SE
J Cell Sci; 2000 Jun; 113 ( Pt 11)():2011-21. PubMed ID: 10806112
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
12. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S
Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452
[TBL] [Abstract][Full Text] [Related]
13. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
14. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
15. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
Loganzo F; Hari M; Annable T; Tan X; Morilla DB; Musto S; Zask A; Kaplan J; Minnick AA; May MK; Ayral-Kaloustian S; Poruchynsky MS; Fojo T; Greenberger LM
Mol Cancer Ther; 2004 Oct; 3(10):1319-27. PubMed ID: 15486199
[TBL] [Abstract][Full Text] [Related]
16. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.
Allen JD; Brinkhuis RF; Wijnholds J; Schinkel AH
Cancer Res; 1999 Sep; 59(17):4237-41. PubMed ID: 10485464
[TBL] [Abstract][Full Text] [Related]
17. Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
[TBL] [Abstract][Full Text] [Related]
18. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Minderman H; O'Loughlin KL; Pendyala L; Baer MR
Clin Cancer Res; 2004 Mar; 10(5):1826-34. PubMed ID: 15014037
[TBL] [Abstract][Full Text] [Related]
19. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
